Asgard Therapeutics will present new preclinical data on its lead asset AT‑108 in an oral presentation at the ASGCT Annual Meeting, taking place from 11–15 May in Boston.
AT‑108 is a first‑in‑class, off‑the‑shelf cancer immunotherapy designed to induce powerful, personalised anti‑cancer responses by forcing tumour cells to present their own antigens to the immune system.
The company said the new findings advance the programme across several dimensions, including demonstrating systemic, dose‑dependent efficacy and identifying biomarker parameters to explore in future clinical studies.
Fábio Rosa, Co‑founder and VP and Head of Research at Asgard Therapeutics, who will deliver the presentation, said: “These data demonstrate the ability of AT-108 to reprogram tumor cells in situ into antigen-presenting cells with high efficiency, systematically driving activation of tumor-specific immune responses within the tumor microenvironment.
“This work provides clear preclinical evidence supporting our in vivo cell reprogramming platform and represents another milestone for Asgard as we advance AT-108 toward the clinic.”
Shane Olwill, Chief Development Officer at Asgard Therapeutics, said: “We are delighted to have been selected for an oral presentation at ASGCT, which will highlight the progress we have made advancing AT-108 – our first-in-class, off-the-shelf gene-based immunotherapy designed to trigger powerful, personalised anti-cancer responses. Our pioneering approach to tackling cancer is potentially transformative and we are excited by AT-108’s broad potential across multiple cancer types.”
Earlier work showed that intratumoral delivery of AT‑018, an earlier candidate, reprogrammed tumour cells into cDC1‑like antigen‑presenting cells and worked synergistically with immune checkpoint blockade.
The new study demonstrates AT‑108’s ability to induce systemic anti‑tumour immunity in mouse models, including abscopal effects and regression of non‑treated tumours.
It also establishes AT‑108 as the optimised clinical candidate following screening of more than 25 cassette variants, defines dosing and treatment parameters required for durable responses, and identifies pharmacodynamic biomarkers linked to reprogramming and immune activation.
